Stocks · News reference
Castle Biosciences To Present New Data From Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test At ACG 2026 Annual Scientific Meeting And Postgraduate Course
Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacyAmong patients surveyed in the study, 94% of those open to a new systemic therapy expressed
Castle Biosciences Announces Opening Of New Laboratory And Office Facility In Scottsdale, Arizona
New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growthFRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences,